Silvia Damian

11PUBLICATIONS
75CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyMolecular targetsCancer geneticsFormal methods for software
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 09, 2025
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization.

Daniele Lorenzini, Rebecca Salvatori, Chiara Costanza Volpi

|Jun 11, 2025
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.

Federico Nichetti, Marta Brambilla, Matteo Duca

|Dec 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.

Jason J Luke, Karen Gelmon, Lillian L Siu

|Sep 23, 2024
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?

Jacopo Azzollini, Iolanda Capone, Matteo Duca

|May 24, 2024
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Jordi Rodón, Silvia Damian, Muhammad Furqan

|May 06, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Jordi Rodón, Silvia Damian, Muhammad Furqan

Pageof 2

Frequent Collaborators

6 joint publications

Luca Agnelli

4 joint publications

Andrea Vingiani

4 joint publications

Alberta Piccolo

4 joint publications

Federico Nichetti